Company profile
Inovio Pharmaceuticals, Inc.
NASDAQ: INO · Healthcare · Biotechnology
#1069 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
37DFH 16DQ 71GM 14SS 71
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$84.9M
Employees
112
as of 2026-08-19
Market cap
$82.9M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$65.3k$65.3k2025
Net income-$84.9M-$84.9M2025
Operating income-$86.8M-$86.8M2025
Total assets$74.3M$74.3M2025
Liabilities$50.2M$50.2M2025
Equity$24.1M$24.1M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable Segments100%
By geography
Not disclosed.
The read
What is Inovio Pharmaceuticals, Inc.’s revenue?
Inovio Pharmaceuticals, Inc. booked $65.3k in FY2025 revenue, contracting 70% year over year — slower than 86% of Healthcare companies we track, at a -130000.0% net margin.
Peers · Healthcare
Vivos Inc.48DNeutra Corp.——Aquarius Surgical Technologies Inc.——Kali, Inc.——Connect Biopharma Holdings Limited25DOxford Investments Holdings Inc.——Neighbors
Montgomery →Key facts
CEOJacqueline E. Shea
SectorHealthcare
IndustryBiotechnology
HeadquartersPlymouth Meeting, PA
ExchangeNASDAQ: INO
Employees112
IPO date1998-12-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.